Willow vs Enhance MD: Pricing, support, and compound options compared
Comparing Willow vs Enhance MD quickly: Willow emphasizes a structured, telehealth-first oral GLP-1 program with progress tracking and follow-up support, while Enhance MD emphasizes low first-month pricing and flat-rate compounded semaglutide and tirzepatide. Early verdict: choose Willow if you prioritize ongoing behavioral support and progress tracking; choose Enhance MD if you prioritize lowest first-month cost and multi-compound access.
Explore Willow’s telehealth program
How Willow vs Enhance MD differ at a glance
This comparison focuses on the most distinctive differences supported by the sources: starting price and introductory offers, pricing model and dose escalation, compound availability, support and follow-up features, and regulatory notes about compounded medications. Treatment availability for both platforms is subject to clinician review: “Treatment is available only when a licensed clinician determines it is medically appropriate.”
Price and introductory offers
Willow lists a starting price of 299. Enhance MD advertises semaglutide “from $49” for the first month and tirzepatide “from $99” for the first month. Enhance MD’s $49/$99 rates are explicitly first-month introductory prices.
See Enhance MD first-month pricing
Pricing model and dose escalation
Willow is presented as a structured program rather than a medication subscription; the captured evidence does not detail whether pricing changes with dose. Enhance MD promotes flat-rate pricing “that stays the same at every dose, no fee escalation” after the introductory period, which it positions as a way to avoid escalating costs during titration.
Compound and treatment options
Willow’s evidence emphasizes an oral GLP-1 program; the source does not list multiple compounds. Enhance MD explicitly offers both compounded semaglutide and compounded tirzepatide on the same platform, with the first-month prices noted above.
Support, follow-up, and care model
Willow positions itself as “a structured weight management journey” with “progress tracking and follow-up support” and a “licensed telehealth team.” Enhance MD markets “premium medical care for metabolic wellness” and clinician-directed compounds, and notes a large treated patient base (“10,000+ patients treated” in the captured evidence).
Regulatory and medication notes
Both sources include the regulatory qualifier that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Willow notes “Compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.” Enhance MD repeats that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Direct comparison table
| Criteria | Willow | Enhance MD |
|---|---|---|
| Starting price | 299 | Semaglutide from $49 first month; Tirzepatide from $99 first month |
| Pricing model | Structured program; pricing details not captured | Introductory low first-month price, then flat-rate pricing with no dose escalation |
| Compounds available | Oral GLP-1 program (no multiple compounds listed in captured evidence) | Compounded semaglutide and tirzepatide on one platform |
| Support and follow-up | Licensed telehealth team, progress tracking tools, follow-up consultations | Clinician-directed care; claims of 10,000+ patients treated and metabolic lab testing every 6 months in captured evidence |
| Regulatory note | Compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality | Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality |
Key pros and cons compared
Willow
Pros based on captured evidence: simple digital workflow, licensed telehealth team, progress tracking tools, follow-up consultations. Con listed: higher monthly entry pricing for some plans. The captured landing evidence was limited.
Start Willow’s tracked program
Enhance MD
Pros based on captured evidence: lowest first-month pricing for semaglutide and tirzepatide among compared options, flat-rate pricing with no escalation, both compounds available on one platform, and a reported 10,000+ patients treated. Cons: the low $49/$99 rates are explicitly first-month prices and ongoing flat-rate pricing may be higher; medications are compounded and not FDA-approved finished products.
Start Enhance MD pricing and options
Final thoughts on Willow vs Enhance MD
Willow vs Enhance MD splits along support versus entry cost and compound choice. Willow emphasizes structured support, progress tracking, and follow-up with a telehealth team and lists a starting price of 299. Enhance MD emphasizes very low first-month pricing for semaglutide and tirzepatide and a flat-rate model that “stays the same at every dose, no fee escalation” after the introductory period. Both platforms require clinician determination that treatment is medically appropriate, and both note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Choose Willow if…
You prioritize a structured weight management journey with progress tracking, follow-up consultations, and a licensed telehealth team as described in the captured evidence.
Choose Enhance MD if…
You prioritize the lowest first-month entry cost for semaglutide or tirzepatide and want access to both compounded compounds on one platform with flat-rate pricing that avoids dose escalation after the introductory period.